Sandra Horning

Clinical Trials

• Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
• Not Recruiting Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
• Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
• Not Recruiting Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
• Not Recruiting A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
• Not Recruiting A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
• Not Recruiting A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
• Not Recruiting Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
• Not Recruiting High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
• Not Recruiting Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
• Not Recruiting Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
• Not Recruiting Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
• Not Recruiting Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
• Not Recruiting Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
• Not Recruiting Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
• Not Recruiting A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
• Not Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
• Not Recruiting A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
• Not Recruiting A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
• Not Recruiting Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
• Not Recruiting Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
• Not Recruiting Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)
• Not Recruiting 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
• Not Recruiting Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
• Not Recruiting Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma